Ryan Cross

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes will help solve some of the biggest and most competitive challenges in the cell and gene therapy field.

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher and CHOP to develop custom therapies for HLH and metabolic disorders.

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein nanoparticles. CEO Akin Akinc leads development for autoimmune diseases.

SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology. Despite raising $115M, the company struggled with targeting and delivery issues.

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication syndrome, showing improved motor skills after 12 weeks.

Alzheon's valiltramiprosate (ALZ-801) fails Phase 3 trial in Alzheimer's patients with APOE4 gene copies, showing no significant cognitive decline slowdown despite safer profile than competitors.

Gene editing pioneer David Liu was awarded one of three Breakthrough Prizes in Life Sciences for his invention of base and prime editing. The two CRISPR technologies, first published in ...

Shanghai's RiboX Therapeutics begins first-ever circular RNA clinical trial, targeting dry mouth in cancer patients. Company has raised $110M from investors including Boehringer Ingelheim.

Alpha Lee announced a Zika virus-fighting molecule at a chemistry meeting, but later learned his $67M federal funding was cut due to pandemic's end, affecting multiple antiviral research programs.

Turn Biotechnologies acquires drug delivery tech from Harvard & Vesigen Therapeutics to expand mRNA aging therapies; CEO Anja Krammer aims for 2026 clinical trials

Arbor Biotechnologies, a startup founded by CRISPR pioneer Feng Zhang nine years ago, has closed a $73.9 million Series C financing to bring its first therapy into clinical trials � ...

Nosis Bio, a startup developing new ways to deliver RNA therapies to specific cells, has struck partnerships with two pharma companies that together could be worth more than $1.5 billion, the company told Endpoints News in an exclusive interview.

On a sunny September day in 2023, scientists at CRISPR Therapeutics invited me to peer through their microscopes. Through the lens were liver cells, part of the company’s work to gear up for a clinical trial using CRISPR to permanently reduce cholesterol.

The human genome is chock-full of middle managers. Roughly 2,000 proteins, accounting for one-tenth of our genes, control how the rest of our genes are turned ...

Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory loss at ...

Fertility startup Gameto has received permission from the FDA to see if its ovary-in-a-dish technology can make in vitro fertilization a less grueling process, the company told Endpoints News in ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive races.

Nature journal publishes article suggesting embryo gene editing could prevent major diseases, sparking debate. Study by Peter Visscher models how editing DNA could reduce disease risk.

Melissa Moore, ex-Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng and Amit Deshwar.

Baby with genetic OTC deficiency shows promising response to iECURE's first-in-kind gene therapy, potentially avoiding liver transplant and normalizing protein metabolism.